DAX24.130 -0,1%Est505.708 -0,2%MSCI World4.343 -0,1%Top 10 Crypto12,50 ±0,0%Nas23.654 +0,3%Bitcoin76.684 -2,5%Euro1,1697 ±0,0%Öl62,37 -0,2%Gold4.214 -0,4%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Bayer BAY001 NVIDIA 918422 Siemens Energy ENER6Y DroneShield A2DMAA TUI TUAG50 RENK RENK73 Deutsche Telekom 555750 Allianz 840400 TKMS thyssenkrupp Marine Systems TKMS00 Vonovia A1ML7J Lufthansa 823212 Volkswagen (VW) vz. 766403 Novo Nordisk A3EU6F Mercedes-Benz Group (ex Daimler) 710000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX etwas tiefer -- US-Börsen höher -- Fed senkt Leitzins -- GameStop-Zahlen enttäuschen -- Palantir, Lufthansa, Intel, Vonovia, Bayer, Rüstungstitel, Microsoft, Amazon, TUI, TSMC im Fokus
Top News
Berkshire Hathaway oder Broadcom: Welche Aktie bis 2030 mehr Potenzial hat Berkshire Hathaway oder Broadcom: Welche Aktie bis 2030 mehr Potenzial hat
Elon Musk gibt Aktienempfehlung ab: Warum der Tesla-CEO Alphabet und NVIDIA im KI-Rennen vorne sieht Elon Musk gibt Aktienempfehlung ab: Warum der Tesla-CEO Alphabet und NVIDIA im KI-Rennen vorne sieht
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Schlägt dein Herz schon für ETFs? Investier bei der Commerzbank zu Top-Konditionen in Vanguard-ETFs

Eupraxia Pharmaceuticals Aktie

Kaufen
Verkaufen
4,92 EUR -0,08 EUR -1,60 %
FSE
6,29 USD +0,32 USD +5,36 %
BTT
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.259,73 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3EGRS

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINCA29842P1053

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolEPRX

Eupraxia Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireEupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
PR NewswireEupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
PR NewswireEupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
PR NewswireEupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
PR NewswireEupraxia Pharmaceuticals Announces CFO Succession
PR NewswireEupraxia Pharmaceuticals Announces CFO Succession
PR NewswireEupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
PR NewswireEupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
PR NewswireEupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
PR NewswireEupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
PR NewswireEupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
PR NewswireEupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
PR NewswireEupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
PR NewswireEupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
PR NewswireEupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results
PR NewswireEupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results
PR NewswireEupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
PR NewswireEupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
PR NewswireEupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024
PR NewswireEupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024
PR NewswireLancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis
PR NewswireLancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis
PR NewswireEupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024
PR NewswireEupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024
PR NewswireEupraxia Pharmaceuticals Strengthens Senior Management Team
PR NewswireEupraxia Pharmaceuticals Strengthens Senior Management Team
PR NewswireEupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases
PR NewswireEupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases
PR NewswireEupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
PR NewswireEupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
PR NewswireEupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
PR NewswireEupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
PR NewswireEupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results
PR NewswireEupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results
PR NewswireEupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility
PR NewswireEupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility
PR NewswireEupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo
PR NewswireEupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo
PR NewswireEupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024
PR NewswireEupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024

Eupraxia Pharmaceuticals News

Eupraxia Pharmaceuticals News: auf dieser Seite finden Sie alle Eupraxia Pharmaceuticals News und Nachrichten zur Eupraxia Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Eupraxia Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Eupraxia Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.